Get started
Author

Diana Cortés‐Selva

Observed names: Cortes-Selva, Diana, D. Cortes-Selva, Diana CORTES-SELVA, Diana Cortes Selva, Diana Cortes-Selva, Diana Cortes‐Selva, Diana Cortés-Selva
Observed institutions: Johnson & Johnson (United States), Purdue University West Lafayette, University of Utah, University of Florida, Janssen Research & Development (United States), Amsterdam UMC Location Vrije Universiteit Amsterdam
ORCID: 0000-0001-9203-2090
Observed ORCID: 0000-0001-9203-2090
OpenAlex ID: A5043480262
Teclistamab impairs humoral immunity in patients with heavily pretreated myeloma: importance of immunoglobulin supplementation
2023 · Kristine A. Frerichs, Christie P. M. Verkleij, et al. · Blood Advances · 110
PDF
Correlation of immune fitness with response to teclistamab in relapsed/refractory multiple myeloma in the MajesTEC-1 study
2024 · Diana Cortes-Selva, Tatiana Perova, et al. · Blood · 73
PDF
Innate and Innate-Like Cells: The Future of Chimeric Antigen Receptor (CAR) Cell Therapy
2020 · Diana Cortés-Selva, Bidisha Dasgupta, et al. · Trends in Pharmacological Sciences · 61
Global effects of the DEAD ‐box RNA helicase DeaD ( CsdA ) on gene expression over a broad range of temperatures
2014 · Christopher A. Vakulskas, Archana Pannuri, et al. · Molecular Microbiology · 59
PDF
Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Correlative Analyses from MajesTEC-1
2022 · Diana Cortes-Selva, Tineke Casneuf, et al. · Blood · 50
NK Cell Phenotype Is Associated With Response and Resistance to Daratumumab in Relapsed/Refractory Multiple Myeloma
2023 · Christie P.M. Verkleij, Kristine A. Frerichs, et al. · HemaSphere · 40
Schistosome and intestinal helminth modulation of macrophage immunometabolism
2020 · Diana Cortes‐Selva, Keke Fairfax · Immunology · 33
Schistosoma mansoni Infection-Induced Transcriptional Changes in Hepatic Macrophage Metabolism Correlate With an Athero-Protective Phenotype
2018 · Diana Cortes-Selva, Andrew F. Elvington, et al. · Frontiers in Immunology · 29
PDF
Metabolic reprogramming of the myeloid lineage by Schistosoma mansoni infection persists independently of antigen exposure
2021 · Diana Cortes-Selva, Lisa Gibbs, et al. · PLoS Pathogens · 24
PDF
IL‐4 promotes stromal cell expansion and is critical for development of a type‐2, but not a type 1 immune response
2018 · Diana Cortes‐Selva, Andrew Ready, et al. · European Journal of Immunology · 21
PDF
Infections and parameters of humoral immunity with talquetamab in relapsed/refractory multiple myeloma in MonumenTAL-1
2025 · Carolina Schinke, Paula Rodriguez-Otero, et al. · Blood Advances · 20
PDF
Maternal schistosomiasis impairs offspring Interleukin-4 production and B cell expansion
2021 · Diana Cortés-Selva, Lisa Gibbs, et al. · PLoS Pathogens · 15
PDF
P32 Majestec-1: Correlative Analyses of Teclistamab, a B-cell Maturation Antigen (bcma) X Cd3 Bispecific Antibody, in Patients With Relapsed/refractory Multiple Myeloma (rrmm)
2023 · N. van de Donk, D. Cortes-Selva, et al. · HemaSphere · 8
Talquetamab, a GPRC5D×CD3 bispecific antibody, in combination with pomalidomide in patients with Relapsed/Refractory multiple myeloma: Updated safety and efficacy results from the Phase 1b monumental-2 study
2025 · Hang Quach, Aurore Perrot, et al. · Blood · 4
PDF
Longitudinal mechanisms of response, resistance and relapse to teclistamab in multiple myeloma: results from MajesTEC-1
2026 · Deeksha Vishwamitra, Sheri Skerget, et al. · Haematologica · 2
PDF
Schistosoma mansoni antigen induced innate immune memory features mitochondrial biogenesis and can be inhibited by ovarian produced hormones
2025 · Juan Marcos Oviedo, Diana Cortes-Selva, et al. · bioRxiv (Cold Spring Harbor Laboratory) · 2
P47 | Utility and Sensitivity of Wett-sa53 to Measure Dysgeusia Associated With Talquetamab, a Gprc5d×cd3 Bispecific Antibody, in Relapsed/refractory Multiple Myeloma: Preliminary Data From the Talisman Study
2026 · R. Popat, N.W.C.J. Van De Donk, et al. · Haematologica · 1
PDF
Interleukin-4 (IL-4) maintains lymphocyte-stromal cell axis in peripheral lymph nodes
2017 · Diana Cortes Selva, Andrew L Ready, et al. · The Journal of Immunology · 1
Early Resolution of Talquetamab Oral Side Effects in Relapsed/refractory Multiple Myeloma (rrmm): Updated Waterless Empirical Taste Test (wett) and Patient Reported Outcomes (pro) Data From Talisman
2026 · Niels Wcj VAN DE DONK, Rakesh POPAT, et al. · Hematology Transfusion and Cell Therapy
Infections in MonumenTAL-1: a plain language summary of talquetamab treatment for relapsed/refractory multiple myeloma
2026 · Carolina Schinke, Paula Rodríguez-Otero, et al. · Future Oncology
PDF
MM-793: Early Resolution of Talquetamab Oral Side Effects in Relapsed/Refractory Multiple Myeloma: Updated Waterless Empirical Taste Test and Patient-Reported Outcomes Data From TALisman
2026 · Niels WCJ van de Donk, Rakesh Popat, et al. · Clinical Lymphoma Myeloma & Leukemia
POSTER: MM-793: Early Resolution of Talquetamab Oral Side Effects in Relapsed/Refractory Multiple Myeloma: Updated Waterless Empirical Taste Test and Patient-Reported Outcomes Data From TALisman
2026 · Niels Wcj van de Donk, Rakesh Popat, et al. · Clinical Lymphoma Myeloma & Leukemia
Talquetamab with pomalidomide in patients with relapsed/refractory multiple myeloma (RRMM) : updated safety/efficacy from MonumenTAL-2
2026 · Boyd, Kevin, Quach, Hang, et al. · Ghent University Academic Bibliography (Ghent University)
Utility and sensitivity of wett-SA53 to measure dysgeusia associated with talquetamab, a GPRC5D×CD3 bispecific antibody, in Relapsed/Refractory multiple myeloma: Preliminary data from the talisman study
2025 · Rakesh Popat, Niels W.C.J. van de Donk, et al. · Blood
PDF
Immune Profiling of Multiple Myeloma Patients Treated with Daratumumab Monotherapy: Acquired and Primary Daratumumab-Resistance Is Associated with NK Cell Exhaustion
2021 · Christie P.M. Verkleij, Kristine A. Frerichs, et al. · Blood
Works count: 26
Citation count: 553
H-index: 12
I10-index: 12
Year
Topic
Type